Увійти

Готові списки джерел за темами / Hypertensive neuroretinopathy

Зміст

Статті в журналах

Добірка наукової літератури з теми "Hypertensive neuroretinopathy"

Автор: Grafiati

Опубліковано: 3 червня 2025

Оновлено: 31 липня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Hypertensive neuroretinopathy".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Hypertensive neuroretinopathy"

1

Peresypkina, Anna, Alexandr Dolzhikov, Viktoriya Gubareva, Elena Levkova, and Anna Shabelnikova. "THE DEVELOPMENT OF HYPERTENSIVE NEURORETINOPATHY MODEL ON WISTAR RATS." Research Results in Pharmacology 3, no. (1) (2017): 18–31. https://doi.org/10.18413/2500-235X-2017-3-1-18-31.

Повний текст джерела

Анотація:

A model of hypertensive neuroretinopathy was developed on Wistar line rats with administration of non-selective NO-synthase blocker N-nitro-L-arginine methyl ester (L-NAME) in a dose 12.5 mg/kg within 28 days on the background of single increased intraocular pressure (IOP) to 110 mmHg. As a result of the interim evaluation of pathology simulation mode the most optimal was a model of hypertensive neuroretinopathy with 5-minute increased IOP at day 26 of the experiment on the background of L-NAME for further study of neuroretinoprotective properties of pharmacological agents. Changes formation o

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Anna, A. Peresypkina* Anton L. Pazhinsky Anna S. Pobeda Alexander A. Dolzhikov Nina I. Zhernakova Olga A. Osipova Alexander P. Grigorenko Viktor A. Ruzhenkov. "THE DEVELOPMENT OF HYPERTENSIVE NEURORETINOPATHY MODEL." Indo American Journal of Pharmaceutical Sciences 04, no. 10 (2017): 3695–700. https://doi.org/10.5281/zenodo.1019417.

Повний текст джерела

Анотація:

Introduction: It should be noted the relevance of developing an adequate model of hypertensive neuroretinopathy for further study of neuroretinoprotective properties of pharmacological agents. Research tasks: Development of the methodical approaches for evaluation of the neuroretino protective activity of pharmacological agents to objectively assess the degree of the protective activity of new and commonly used neuroretinoprotectors in ophalmology. Methods: To investigate the fundus of experimental animals a direct ophthalmoscopy was used on 29th day of the experiment. The eye drops Irifrin 2.

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Peresypkina, Anna A. "A comparative evaluation of the efficacy of dimethylaminoethanol derivative 7–16, C7070 and picamilon in correction of experimental hypertensive neuroretinopathy." Research Results in Pharmacology 4, no. 3 (2018): 1–8. http://dx.doi.org/10.3897/rrpharmacology.4.29388.

Повний текст джерела

Анотація:

Introduction. The efficacy of dimethylaminoethanol (DMAE) derivative 7–16, substance C7070 in comparison with picamylon in hypertensive neuroretinopathy model in white laboratory rats was evaluated. Materials and methods. For measuring the blood pressure, a system of noninvasive blood pressure measurement in small animals NIBP200 was used. Ophthalmoscopy was performed by using Bx a Neitz ophthalmoscope (Japan) and Osher MaxField 78D lens, OI-78M model. Electroretinography (ERG) was recorded in response to a single stimulation. Biopotentials were presented graphically on the screen with the hel

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Peresypkina, Anna A. "A comparative evaluation of the efficacy of dimethylaminoethanol derivative 7–16, C7070 and picamilon in correction of experimental hypertensive neuroretinopathy." Research Results in Pharmacology 4, no. (3) (2018): 1–8. https://doi.org/10.3897/rrpharmacology.4.29388.

Повний текст джерела

Анотація:

Introduction. The efficacy of dimethylaminoethanol (DMAE) derivative 7–16, substance C7070 in comparison with picamylon in hypertensive neuroretinopathy model in white laboratory rats was evaluated. Materials and methods. For measuring the blood pressure, a system of noninvasive blood pressure measurement in small animals NIBP200 was used. Ophthalmoscopy was performed by using Bx a Neitz ophthalmoscope (Japan) and Osher MaxField 78D lens, OI-78M model. Electroretinography (ERG) was recorded in response to a single stimulation. Biopotentials were presented graphically on the screen with the hel

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Kumar, Vinod, Ruchir Tewari, Dev Yadav, and SJ Vikas. "Acute macular neuroretinopathy in a young hypertensive patient." Clinical and Experimental Optometry 100, no. 3 (2016): 288–90. http://dx.doi.org/10.1111/cxo.12466.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Lugovskoy, Sergey S., Sofia S. Chernyaeva, Anna A. Peresypkina, et al. "Correction of hypertensive retinal changes in rats with Semax." RESEARCH RESULTS IN BIOMEDICINE 7, no. 3 (2021): 272–80. http://dx.doi.org/10.18413/2658-6533-2021-7-3-0-6.

Повний текст джерела

Анотація:

Currently, there are no drugs for the specific treatment of hypertensive retinal changes. The main therapy is for the treatment of a systemic disease – hypertensive disease. Therefore, the search for ways of specific pharmacological correction of hypertensive retinal changes is of great interest. The aim of the study: To evaluate the correction possibility of retinal injuries with Semax in a rat model of hypertensive neuroretinopathy. Materials and methods: The model was performed by injection of N-nitro-L-arginine methyl ester (L-NAME) at a dose of 1.25 mg/100 g of rat mass within 28 days and

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Gubareva, Victoria O., Anton L. Pazhinsky, Sergey S. Lugovskoy, et al. "Pharmacological correction of morphofunctional retinal injury using 11-amino acid fragment of darbepoetin in the experiment." Research Results in Pharmacology 5, no. 3 (2019): 43–55. http://dx.doi.org/10.3897/rrpharmacology.5.38730.

Повний текст джерела

Анотація:

Introduction: The retinoprotective effect of the 11-amino acid fragment of darbepoetin PRK-002 on the models of hypertensive retinal angiopathy and hypertensive neuroretinopathy in Wistar rats was investigated in comparison with carbamylated darbepoetin and sulodexide. Materials and methods: The protective effects of the pharmacological agents were assessed using the following criteria: a semi-quantitative assessment of changes in the eye fundus when performing ophthalmoscopy, the retinal blood flow, the b/a coefficient, eNOs expression in retinal vessels, specific number of neuronal nuclei in

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Gubareva, Victoria O., Anton L. Pazhinsky, Sergey S. Lugovskoy, et al. "Pharmacological correction of morphofunctional retinal injury using 11-amino acid fragment of darbepoetin in the experiment." Research Results in Pharmacology 5, no. (3) (2019): 43–55. https://doi.org/10.3897/rrpharmacology.5.38730.

Повний текст джерела

Анотація:

Introduction: The retinoprotective effect of the 11-amino acid fragment of darbepoetin PRK-002 on the models of hypertensive retinal angiopathy and hypertensive neuroretinopathy in Wistar rats was investigated in comparison with carbamylated darbepoetin and sulodexide. Materials and methods: The protective effects of the pharmacological agents were assessed using the following criteria: a semi-quantitative assessment of changes in the eye fundus when performing ophthalmoscopy, the retinal blood flow, the b/a coefficient, eNOs expression in retinal vessels, specific number of neuronal nuclei in

Стилі APA, Harvard, Vancouver, ISO та ін.

9

PERESYPKINA, A. A., M. V. POKROVSKII, V. O. GUBAREVA, and E. A. LEVKOVA. "CORRECTION OF HYPERTENSIVE NEURORETINOPATHY BY DIMETHYLAMINOETHANOL DERIVATIVE 7-16 IN EXPERIMENT." Kubanskij nauchnyj medicinskij vestnik 25, no. 1 (2018): 103–7. http://dx.doi.org/10.25207/1608-6228-2018-25-1-103-107.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Niu, Yali, Guoheng Zhang, Xiaojia Sun, Shikun He, and Guorui Dou. "Distinct Role of Lycium barbarum L. Polysaccharides in Oxidative Stress-Related Ocular Diseases." Pharmaceuticals 16, no. 2 (2023): 215. http://dx.doi.org/10.3390/ph16020215.

Повний текст джерела

Анотація:

Oxidative stress is an imbalance between the increased production of reactive species and reduced antioxidant activity, which can cause a variety of disturbances including ocular diseases. Lycium barbarum polysaccharides (LBPs) are complex polysaccharides isolated from the fruit of L. barbarum, showing distinct roles in antioxidants. Moreover, it is relatively safe and non-toxic. In recent years, the antioxidant activities of LBPs have attracted remarkable attention. In order to illustrate its significance and underlying therapeutic value for vision, we comprehensively review the recent progre

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!